FDA's Expedited IND pilot draws 100+ applicants as CBER tests rolling pre-IND review

What happened

FDA's Center for Biologics Evaluation and Research (CBER) has closed applications to its Expedited IND pilot after receiving more than 100 submissions. Selections are due by 18 December. The pilot sits under HHS Operation TrialBlazer. Its stated purpose is to test whether outside expert institutions and rolling review can speed first-in-human trials without lowering safety or oversight standards.

A second CBER document sets out how the pilot will work. Sponsors will submit discipline-specific components during pre-IND development, not as one package at the end. A "QRI" will vet each component before the 30-day review begins. The records do not spell out what QRI stands for or how reviewers will be chosen, so those details should be confirmed in FDA's own materials. According to CBER, most pilot activity will happen before the formal IND is filed.

Why the design matters

Normally, an IND is submitted as a complete package. Under US rules, the trial can generally start once 30 days have passed without FDA imposing a clinical hold. Early development questions, such as chemistry and manufacturing, pharmacology and toxicology, and clinical protocol design, are usually worked through in sponsor planning and optional pre-IND interactions. The formal clock starts only when the full file arrives.

The pilot moves part of that work forward. If each component is vetted as it is submitted, problems in one discipline can surface while the rest of the program is still being built. The formal 30-day review then starts from a file that has already been through a filter. Whether that saves time overall is the pilot's central question. The records give no data on timelines, so any claim of speed gains would be premature.

The phrase "without lowering safety or oversight standards" is the commitment to watch. Rolling review shifts when scrutiny happens. It does not remove it. Sponsors should not read the pilot as a lighter-touch route.

The wider trial-start landscape

FDA is not the only regulator working on early trial-start friction. On 3 November, ACT EU said its clinical trial application advice pilot will become a permanent service from January 2027. The pre-submission advice procedure is for sponsors using CTIS and has run since 2024. It will continue with updated guidance and templates.

On 4 November, the MHRA published guidance on how it will assess non-clinical data generated outside the OECD Mutual Acceptance of Data (MAD) system. It explains when UK trial applications relying on such safety data may be considered. It describes enhanced assessment in limited circumstances and a programme of test facility inspections.

These are different tools. FDA's pilot is about sequencing and vetting. ACT EU's service is about advice before submission. The MHRA guidance is about data provenance. All three point the same way: regulators are trying to resolve questions earlier in the pathway, before a full application is filed or judged.

Who is affected

Sponsors of first-in-human biologics programs under CBER are the direct audience. More than 100 applications suggests strong interest, though the records do not say how many will be selected or what the selection criteria are. Applicants that are not chosen will continue under the standard IND pathway.

Sponsors planning multi-region programs face a practical issue. A rolling, component-by-component US pre-IND process will not match an EU CTIS application or a UK submission. Teams will need to decide which data packages are frozen first and how to keep them consistent across regions. The MHRA guidance is especially relevant if non-clinical studies were run at facilities outside the OECD MAD system.

Companies further along also show how much early-stage interaction shapes later plans. Xencor said it plans to meet FDA in the first half of 2027 on a possible accelerated approval route for XmAb819, citing a 45.5% response rate in kidney cancer. Arvinas reported first patients dosed with ARV-6723 in a Phase 1/2 solid tumour trial and said it plans EU and UK filings for ARV-102 in PSP. Neither company is part of the pilot according to the records. Both illustrate sponsors working across regions and stages.

What to watch

The first marker is the 18 December selection date. Watch for how many sponsors are chosen, what product types they represent, and whether FDA publishes the selection criteria. Also watch for any description of the outside expert institutions' role, which the records do not detail.

The second is evidence of results. The records contain no outcome data. Useful measures would be time from first component to first-in-human dosing, how often vetting finds deficiencies early, and whether clinical holds fall. None of this is known yet.

The third is whether the model spreads. It is not yet known whether FDA would extend rolling pre-IND review beyond the pilot or beyond CBER.